In this study, we sought to engineer a novel human anti-TIM-4 antibody with potent biological activity to act as a potentiator of checkpoint inhibition in cancers the exhibit innate or adaptive resistance to immunotherapy. The gene discussed is TIMD4; the disease is cancer.